Background
Ginger Casper Combs received an injection of Magnevist, an FDA-approved gadolinium-based contrast agent, in March 2016 for an MRI following a motor vehicle accident. She subsequently developed symptoms she attributed to gadolinium retention in her body, and in 2018, amended her complaint to assert that she suffered from Gadolinium Deposition Disease (GDD). Combs sued Bayer for failure to warn, design defect, negligence, and various fraud claims, alleging that Bayer knew gadolinium could be retained in the body but failed to warn patients or physicians of this risk and its purported health consequences.
Magnevist had been FDA-approved since 1988 and bore warnings regarding nephrogenic systemic fibrosis (NSF) in patients with renal impairment, but no warnings regarding gadolinium retention in patients with normal kidney function. In 2015, the FDA began investigating potential risks associated with gadolinium-based contrast agents, and Bayer established an internal gadolinium deposition task force. However, Bayer and the FDA consistently stated they had found no evidence of a causal relationship between gadolinium retention and adverse health effects in patients with normal renal function.
Bayer moved for summary judgment on all claims, asserting federal preemption, reliance on a statutory presumption of non-liability for FDA-approved products, and that the learned intermediary doctrine precluded liability. The trial court granted summary judgment in its entirety.
The Court’s Holding
The Oklahoma Court of Civil Appeals affirmed, holding that Combs’ failure-to-warn claims were preempted by federal law because Combs failed to establish that Bayer could have unilaterally revised Magnevist’s warning label under the FDA’s “changes being effected” (CBE) regulation. Under 21 C.F.R. § 314.70, manufacturers may change drug labels to “add or strengthen a warning” only when “newly acquired information” reveals “reasonable evidence of a causal association” with a clinically significant adverse health effect. The court found that Combs presented no evidence that such a causal relationship had been established before her March 2016 injection. Evidence that gadolinium was retained in the body and that adverse events had been reported was insufficient; federal regulations require reasonable evidence of a causal link, not mere retention of a substance or isolated adverse event reports.
The court rejected Combs’ argument that Bayer’s internal awareness of gadolinium retention or any alleged concealment from the FDA created a duty to unilaterally change warnings, finding her factual assertions unsupported by the evidence. The court also affirmed summary judgment under Oklahoma’s statutory presumption of non-liability for FDA-approved products (76 O.S.2021, § 57.2), which Combs failed to rebut. Additionally, the court held that even assuming an inadequate warning, Combs’ physician testified he would not have altered his treatment based on additional warnings regarding gadolinium retention and GDD, defeating proximate cause under the learned intermediary doctrine.
Key Takeaways
- State law failure-to-warn claims against pharmaceutical manufacturers are preempted when the manufacturer could not have unilaterally changed the drug label under FDA regulations, even absent express preemption language.
- The “newly acquired information” standard under the CBE regulation requires reasonable evidence of a causal association between a drug and clinically significant harm—evidence of a substance’s retention or isolated adverse event reports standing alone are insufficient.
- Oklahoma’s statutory presumption of non-liability for FDA-approved products provides manufacturers with substantial protection at summary judgment where plaintiffs cannot establish either that federal safety standards were inadequate or that information was withheld from the FDA.
- Under the learned intermediary doctrine, even if a manufacturer fails to warn adequately, summary judgment is appropriate if the treating physician would not have altered treatment based on additional warnings, defeating the proximate cause element.
Why It Matters
This decision is significant for product liability practitioners handling pharmaceutical cases because it defines the boundaries of manufacturer liability when scientific consensus has not yet established a causal link between a drug component and alleged harms. The court’s holding—that regulatory preemption turns on whether newly acquired evidence of causation existed at the relevant time, not merely on awareness of adverse event reports or knowledge that a substance is retained—sets a high bar for failure-to-warn plaintiffs and reflects deference to FDA scientific determinations. The decision also underscores the interplay between federal pharmaceutical regulation and state tort law, clarifying that manufacturers cannot be forced by state law to exceed what federal law permits them to do unilaterally.
The case has implications beyond Magnevist and gadolinium. As medical and scientific understanding of drug components evolves, manufacturers and their counsel will look to this decision to understand when the evidentiary threshold for a causal relationship has been crossed. The court’s affirmation that isolated adverse event reports, internal task forces, and FDA investigations do not trigger a duty to update warnings unless supported by established causal evidence reflects a regulatory framework that protects manufacturers from hindsight-based liability while awaiting scientific consensus. This outcome may be instructive in other mass-exposure pharmaceutical contexts where causation remains disputed or scientifically unsettled.